熊锡山，男，主治医师，讲师。曾师从中华医学会肾脏病分会副主任委员、上海市肾脏病分会主任委员梅长林教授，2008年6月底获第二军医大学肾脏病学博士学位，毕业后分配至军事医学科学院附属医院肾内科，现职称是主治医师。 曾参与完成了多项科研课题： 　一、新型酪氨酸激酶抑制剂的研发和治疗多囊肾病的实验研究 ( 国家科技部863 项目编号:2002AA2Z3130 金额300万); 　二、PPARγ激动剂的研发及治疗多囊肾病实验研究( 国家科技部863 项目编号: 2007AA02Z3Z1 金额50万)。 　以第一作者身份共发表SCI收录论著5篇，以共同第一作者身份发表SCI收录论著1篇，以其他作者身份发表SCI收录论著5篇。获得专利2项，多年从事肾脏病基础及临床研究，对各种常见肾脏疾病、急慢性肾功能不全、血液净化、多囊肾病的临床救治，经验丰富。 目前已发表的文章: 　1. Pyrimidinyl-arylpropionic acid derivatives: viable resources in the development of new antineoplastic agents. Xiong Xishan, Wang L, Ye Y, Fu L, Chen M, Wang Q, Liu M, Tang J, Dai B, Shen J, Mei C. Invest New Drugs. 2009 Jun 17. [Epub ahead of print] 2. B5, a novel pyrrole-substituted indolinone, exerts potent antitumor efficacy through G2/M cell cycle arrest. Xiong Xishan, Zhang Y, Gao X, Dong Z, Li L, Ji C, Fu L, Luo X, Liu H, Mei C. Invest New Drugs. 2010 Feb;28(1):26-34. Epub 2009 Jan 13. 3. Antitumor activity of a new N-substituted thiourea derivative, an EGFR signaling-targeted inhibitor against a panel of human lung cancer cell lines. Xiong Xishan, Liu H, Fu L, Li L, Li J, Luo X, Mei C. Chemotherapy. 2008;54(6):463-74. Epub 2008 Oct 2. 4. Antitumor activity of a novel series of alpha-aryloxy-alpha-methylhydrocinnamic acid derivatives as PPAR gamma agonists against a panel of human cancer cell lines. Xiong Xishan, Ye Y, Fu L, Dai B, Liu J, Jia J, Tang J, Li L, Wang L, Shen J, Mei C. Invest New Drugs. 2009 Jun;27(3):223-32. Epub 2008 Aug 13. 5. Antitumor activity of a novel EGFR tyrosine kinase inhibitor against human lung carcinoma in vitro and in vivo. Xiong Xishan, Fu L, Wang L, Cai H, Li L, Jiang H, Duan W, Mei C. Invest New Drugs. 2009 Feb;27(1):1-11. Epub 2008 May 21. 6. Antitumor efficacy of two novel non-thiazolidinedione compounds as peroxisome proliferator-activated receptor-gamma agonists in human osteosarcoma cells in vitro. Fu L, Xiong Xishan, Wang L, Gao X, Ye Y, Jia J, Hu H, Li L, Shen J, Mei C. Chemotherapy. 2009;55(6):468-76. Epub 2009 Dec 9. 7. Mycophenolate mofetil versus Rapamycin in Han: SPRD rats with Polycystic Kidney Disease. Zhang T, Wang L, Xiong Xishan, Mao Z, Wang L, Mei C. Biol Res. 2009;42(4):437-44. Epub 2010 Jan 29. 8. DH9, a novel PPARgamma agonist suppresses the proliferation of ADPKD epithelial cells: An association with an inhibition of beta-catenin signaling. Liu M, Fu L, Liu C, Xiong Xishan, Gao X, Xiao M, Cai H, Hu H, Wang X, Mei C. Invest New Drugs. 2009 Sep 16. [Epub ahead of print] 9. Identification of phosphoproteins in kidney tissues from patients with autosomal dominant polycystic kidney disease. Yawei Liu, Bing Dai, Changlin Mei, Yan Zhang, Xiong Xishan, Richard Sandford. Proteomics - Clinical Applications. Volume 2 Issue 7-8, Pages 1153 - 1166 10. Design, synthesis and antitumor evaluation of a new series of N-substituted-thiourea derivatives.. Li J, Tan JZ, Chen LL, Zhang J, Shen X, Mei CL, Fu LL, Lin LP, Ding J, Xiong B, Xiong Xishan, Liu H, Luo XM, Jiang H

常见肾脏疾病、急慢性肾功能不全、血液净化、多囊肾病

讲师